T cells targeting a mutated neoantigen peptide achieved complete and durable tumor regression in mice with less toxic pre-treatment, demonstrating that neoantigen-focused immunotherapy may be both more effective and safer.
Complete durable regressionT cells targeting a mutated neoantigen peptide achieved complete and lasting regression of large, established tumors in mice — with less lymphodepleting conditioning than wild-type peptide targeting.
What the researchers found
T cells from pmel-1 transgenic mice targeting the mutated (neoantigen) version of the gp100 peptide showed enhanced recognition as measured by IFN-γ production. When used in adoptive cell transfer, neoantigen-targeting T cells achieved complete and durable regression of large, established, vascularized B16 melanoma tumors.
Critically, neoantigen targeting required less lymphodepleting conditioning than targeting the wild-type peptide, suggesting reduced treatment toxicity. The study also uncovered that enforced expression of the IL-2 receptor alpha chain (CD25) on mutation-reactive CD8+ T cells further improved their anti-tumor function, revealing a new strategy for enhancing neoantigen-targeted immunotherapy.
Why it matters
Adoptive T cell therapy has shown remarkable results in some cancer patients, but its effectiveness and toxicity vary widely. This study provides a preclinical model demonstrating that targeting mutated neoantigens — rather than normal self-proteins — can improve both effectiveness and safety. The reduced need for toxic lymphodepletion is particularly significant, as pre-treatment conditioning is one of the major barriers to wider clinical adoption of cell-based immunotherapy.
How the study worked
Researchers used pmel-1 T cell receptor-transgenic mice whose T cells recognize the gp100 peptide. B16 melanoma cells were gene-engineered to express either wild-type or mutated gp100 epitopes. Adoptive cell transfer experiments were conducted in tumor-bearing mice with varying levels of lymphodepleting conditioning. T cell recognition was measured by IFN-γ production. The effect of enforced CD25 expression on CD8+ T cell anti-tumor function was also evaluated.
What this study cannot tell us
This is a mouse model study using a transgenic system with a single known neoantigen, which is far simpler than human cancers with many mutations. The B16 melanoma model is well-characterized but may not represent the diversity of human tumor types. The engineered neoantigen expression may not fully replicate natural neoantigen presentation in human cancers. Translation to human clinical settings requires identifying patient-specific neoantigens, which remains technically challenging.
How to read the evidence
Published in JCI Insight (a high-impact journal), this is a well-designed preclinical study using transgenic mouse models. While mechanistically rigorous, it represents an animal model system rather than clinical evidence.
When this study was published
Published in 2019, this study contributed to the foundational understanding of neoantigen-targeted immunotherapy. The field has since advanced significantly, with neoantigen-based therapies entering clinical trials.
The bigger picture
Neoantigen-targeted immunotherapy is one of the most promising frontiers in personalized cancer medicine. This study validates the concept that mutated peptides are superior targets compared to normal self-proteins, providing mechanistic support for the clinical efforts to identify and target patient-specific neoantigens. The finding about CD25 engineering adds a practical tool for improving neoantigen-reactive T cells that could be incorporated into future clinical protocols.
Questions still open
- Can the CD25 overexpression strategy be safely applied to human neoantigen-reactive T cells for clinical adoptive cell therapy?
- How does this model inform the selection of neoantigen targets in patients with hundreds of tumor-specific mutations?
- Would combining neoantigen-targeted ACT with checkpoint inhibitors further reduce the need for lymphodepleting conditioning?
Common questions
What are neoantigens and why are they important for cancer treatment?
How does targeting neoantigens make cancer immunotherapy safer?
Read the original research
An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.
JCI insight, 4(10)
Citation
Hanada, Ken-Ichi; Yu, Zhiya; Chappell, Gabrielle R; Park, Adam S; Restifo, Nicholas P. (2019). An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.. JCI insight, 4(10). https://doi.org/10.1172/jci.insight.124405